AUROPHARMA1,666.00

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,761 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt6,315.27,941.77,676.27,676.2
Net Debt2,871.22,372.7-262.4-262.4
Total Debt/Equity0.210.240.200.20
Net Debt/Equity0.100.07-0.01-0.01
Total Debt/EBITDA1.081.211.121.12
Net Debt/EBITDA0.490.36-0.04-0.04
Interest Coverage (EBIT/Interest)14.9210.7913.2013.20
Total Debt/Total Capital %17.4619.5716.8516.85
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.